683 Capital Management’s Pyxis Oncology PYXS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$1.66M Buy
714,000
+254,633
+55% +$770K 0.07% 112
2026
Q2
$1.38M Sell
459,367
-436,896
-49% -$835K 0.07% 117
2026
Q1
$1.31M Buy
896,263
+4,353
+0.5% +$6.56K 0.07% 129
2025
Q4
$1.03M Buy
891,910
+366,910
+70% +$1.29M 0.04% 139
2025
Q3
$1.17M Sell
525,000
-20,000
-4% -$28.8K 0.06% 119
2025
Q2
$600K Sell
545,000
-5,000
-0.9% -$5.63K 0.04% 117
2025
Q1
$539K Buy
550,000
+135,000
+33% +$180K 0.04% 127
2024
Q4
$647K Buy
415,000
+344
+0.1% +$992 0.04% 136
2024
Q3
$1.52M Buy
+414,656
New +$1.45M 0.12% 95

Other funds holding PYXS

683 Capital Management's PYXS Position: Q3 2026 in Review

683 Capital Management increased its Pyxis Oncology (PYXS) stake by 55% in Q3 2026, buying an estimated $770K and bringing the position to 714,000 shares worth $1.66M. The position accounts for 0.07% of the portfolio, ranked #112.

683 Capital Management first reported a position in PYXS in Q3 2024 and has held it in 9 quarters since. 101 funds tracked by Wall St. Rank hold PYXS as of Q3 2026.

  • 683 Capital Management held 714,000 shares of Pyxis Oncology worth $1.66M as of Q3 2026.
  • 683 Capital Management bought 254,633 Pyxis Oncology shares in Q3 2026, an estimated $770K.
  • Pyxis Oncology made up 0.07% of 683 Capital Management's portfolio in Q3 2026, its #112 holding.
  • 683 Capital Management first reported a position in Pyxis Oncology in Q3 2024 and has held it in 9 quarters since.
  • 101 funds tracked by Wall St. Rank held Pyxis Oncology as of Q3 2026.

Based on 683 Capital Management's 13F filing for Q3 2026, filed 16 Nov 2026.